...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Therapeutic and Preventive Effects of an Epidermal Growth Factor Receptor Inhibitor on Oral Squamous Cell Carcinoma
【24h】

Therapeutic and Preventive Effects of an Epidermal Growth Factor Receptor Inhibitor on Oral Squamous Cell Carcinoma

机译：表皮生长因子受体抑制剂对口腔鳞状细胞癌的治疗和预防作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Oral squamous cell carcinoma (OSCC) is the sixth most common human neoplasm worldwide. Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is highly expressed in human OSCC and is a target for cancer therapy and prevention. This study investigated the therapeutic and preventive effects of an inhibitor of EGFR (PD153035) on OSCC. METHODS: The effects of PD153035 were examined in human cancer cell lines in vitro, in an athymic nude mouse xenograft model in vivo, and in the 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch tumour model in vivo. RESULTS: PD153035 significantly inhibited cell growth, delayed cell cycle progression and induced apoptosis in human OSCC cells in vitro. In vivo, PD153035 inhibited xenograft tumour growth in nude mice in a dose-dependent manner and prevented the development of OSCC at the postinitiation stage in the DMBA-induced hamster cheek pouch tumour model. PD153035 inhibited the DMBA-induced increases in cell proliferation and in levels of phosphorylated EGFR and phosphorylated signal transducer and activator of transcription 3 (STAT3) protein in the hamster cheek pouch. CONCLUSIONS: Inhibitors of EGFR, such as PD153035, have potential value in the treatment and prevention of OSCC.
机译：目的：口腔鳞状细胞癌（OSCC）是全球第六大最常见的人类肿瘤。表皮生长因子受体（EGFR）是在人OSCC中高度表达的受体酪氨酸激酶，是癌症治疗和预防的靶标。这项研究调查了EGFR抑制剂（PD153035）对OSCC的治疗和预防作用。方法：在人癌细胞系，无胸腺裸鼠异种移植物体内以及在7,12-二甲基苯并[a]蒽（DMBA）诱导的仓鼠脸颊袋肿瘤模型中检测PD153035的作用。结果：PD153035在体外显着抑制人OSCC细胞的生长，延缓细胞周期进程并诱导细胞凋亡。在体内，PD153035在DMBA诱导的仓鼠脸颊袋肿瘤模型中，在启动后阶段以剂量依赖的方式抑制裸鼠的异种移植肿瘤生长，并阻止OSCC的发展。 PD153035抑制了DMBA诱导的仓鼠脸颊袋中细胞增殖以及磷酸化EGFR和磷酸化信号转导子和转录激活因子3（STAT3）蛋白水平的增加。结论：EGFR抑制剂，如PD153035，在OSCC的治疗和预防中具有潜在价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号